“If that would have lessened my symptoms, that would have been great...”: a qualitative study about the acceptability of tecovirimat as treatment for mpox
Abstract Background Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under “exceptional circumstances” based on effectiveness found in pre-clinical challenge studies in animals and safety stu...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-024-03840-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|